LNSR

LENSAR is a commercial-stage cataract-laser maker with a real, growing franchise — FY2025 revenue of $51.7M is up 12.4% YoY and extends a clean four-year ramp from $29.5M in FY2021. The ALLY robotic system (FDA-cleared June 2022, now selling in the U.S., EU and several Asian markets) is the growth engine, and the recurring PID-kit + procedure-license model gives the revenue a subscription-like quality. At a $69.1M market cap and 1.3x sales, the stock is not expensive on the top line alone. That is where the good news ends.

The balance sheet is broken. Stockholders' equity is NEGATIVE $26.0M (down 635% YoY) against an accumulated deficit of $178M, and total liabilities jumped 75.6% to $83.7M with current liabilities up 170.4% to $40.6M. Some of the equity erosion and the gap between the -$24.6M operating loss and the -$34.3M net loss is the non-cash change in fair value of warrant liabilities ($10.3M in 2025, $21.4M in 2024 per the MD&A), but the cash story is the real problem: operating cash flow swung to -$14.8M against just $13.0M of cash on hand. That is roughly one year of runway. Management explicitly flags that 'future capital needs are uncertain and we may need to raise additional funds... such funds may not be available on acceptable terms or at all' — at a $69M cap with negative equity, any raise is likely to be heavily dilutive to the 12.1M share base.